Kotze Paulo Gustavo, Magro Daniela Oliveira, Saab Barbara, Saab Mansur Paulo, Pinheiro Lilian Vital, Olandoski Marcia, Ayrizono Maria de Lourdes Setsuko, Martinez Carlos Augusto Real, Coy Claudio Saddy Rodrigues
Colorectal Surgery Unit, IBD Outpatients Clinic, Cajuru University Hospital, Catholic University of Parana (PUCPR), Curitiba, Brazil.
Colorectal Surgery Unit, Department of Surgery, Campinas State University (UNICAMP), Campinas, Brazil.
Intest Res. 2018 Jan;16(1):62-68. doi: 10.5217/ir.2018.16.1.62. Epub 2018 Jan 18.
BACKGROUND/AIMS: The use of anti-tumor necrosis factor (anti-TNF) agents seems to reduce surgical rates and delay surgical procedures in prospective trials and population-based studies in the management of Crohn's disease (CD). This study aimed to identify whether preoperative anti-TNF agents influence the time from diagnosis to surgery.
An observational retrospective cohort study was conducted on patients with CD submitted to intestinal resections due to complications or medical therapy failure in a period of 7 years. The patients were allocated into 2 groups according to their previous exposure to anti-TNF agents in the preoperative period. Epidemiological aspects regarding age at diagnosis, smoking, perianal disease, and preoperative conventional therapy were considered. A Kaplan-Meier survival analysis was used to outline possible differences between the groups regarding the time to surgery.
A total of 123 patients were included (71 and 52 with and without previous exposure to biologics, respectively). The overall time to surgery was 108±6.9 months (maximum, 276 months). The survival estimation revealed no difference in the mean time to intestinal resection between the groups (99.78±10.62 months in the patients without and 114.01±9.07 months in those with previous anti-TNF use) (log-rank =0.35). There was no significant difference in the time to surgery regarding perianal CD (=0.49), smoking (=0.63), preoperative azathioprine (=0.073) and steroid use (=0.58).
The time from diagnosis to surgery was not influenced by the preoperative use of anti-TNF therapy in this cohort of patients.
背景/目的:在前瞻性试验和基于人群的研究中,使用抗肿瘤坏死因子(抗TNF)药物似乎能降低克罗恩病(CD)治疗中的手术率并延迟手术进程。本研究旨在确定术前使用抗TNF药物是否会影响从诊断到手术的时间。
对7年间因并发症或药物治疗失败而接受肠道切除术的CD患者进行了一项观察性回顾性队列研究。根据患者术前是否接触过抗TNF药物将其分为两组。考虑了诊断时的年龄、吸烟、肛周疾病和术前常规治疗等流行病学因素。采用Kaplan-Meier生存分析来勾勒两组在手术时间上可能存在的差异。
共纳入123例患者(分别有71例和52例曾接触和未接触过生物制剂)。总体手术时间为108±6.9个月(最长276个月)。生存估计显示两组间肠道切除的平均时间无差异(未接触过抗TNF药物的患者为99.78±10.62个月,曾使用过抗TNF药物的患者为114.01±9.07个月)(对数秩检验=0.35)。在肛周CD(=0.49)、吸烟(=0.63)、术前硫唑嘌呤(=0.073)和类固醇使用(=0.58)方面,手术时间无显著差异。
在该队列患者中,从诊断到手术的时间不受术前抗TNF治疗的影响。